Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Stanley B. Cohen"'
Autor:
Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1255-1276 (2023)
Abstract Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spo
Externí odkaz:
https://doaj.org/article/34b105e8c7c24f45a0dae2316f33af1c
Autor:
Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 221-222 (2023)
Externí odkaz:
https://doaj.org/article/099e14f76fec48319dad1e2044b6fc13
Autor:
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 2, Pp 357-373 (2022)
Abstract Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomi
Externí odkaz:
https://doaj.org/article/636def3d7be64a6abbfb716f2f5fce89
Autor:
Stanley B. Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos, K. Lea Sewell
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-13 (2018)
Abstract Background This double-blind, active-controlled, randomized, multinational study evaluated the efficacy, safety, pharmacokinetics (PK), and immunogenicity of PF-06438179/GP1111 (IxifiTM/Zessly®), an infliximab biosimilar, vs infliximab (Rem
Externí odkaz:
https://doaj.org/article/467cbd7fd59e48078e3d671474187104
Autor:
Stanley B Cohen, Eric C Lee
Publikováno v:
Immunotherapy. 14:1183-1190
Summary What is this summary about? Here, we summarize the results from the VOLTAIRE-RA study, originally published in the journal Annals of the Rheumatic Diseases. The VOLTAIRE-RA study looked at how effective and safe BI 695501 is in treating peopl
Autor:
Kevin L. Winthrop, Stanley B. Cohen
Publikováno v:
Nature Reviews Rheumatology. 18:301-304
Autor:
Ruediger B. Mueller, Hendrik Schulze-Koops, Daniel E. Furst, Stanley B. Cohen, Kenneth Kwok, Lisy Wang, Tim Killeen, Johannes von Kempis
Publikováno v:
Clinical Rheumatology. 41:1045-1055
Introduction/objectives We assess the impact of switching versus staying on the same tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis (RA). Methods ORAL Sequel was an open-label, long-term extension study of patients with
Autor:
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen
Publikováno v:
Scientia
This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs.Available data from phase 1, randomized phase 2/3/3b/4 clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89bdb9b44ccbbf9afb8ee0ad5bd81dda
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-502143
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-502143
Autor:
Vibeke Strand, Stanley B. Cohen, Jeffrey R. Curtis, Lixia Zhang, Alan J. Kivitz, Robert W. Levin, Angela Mathis, Erin Connolly-Strong, Johanna B. Withers
Publikováno v:
Expert Review of Molecular Diagnostics. 22:101-109
The molecular signature response classifier (MSRC) is a blood-based precision medicine test that predicts nonresponders to tumor necrosis factor-�� inhibitors (TNFi) in rheumatoid arthritis (RA) so that patients with a molecular signature of non-
Autor:
Virginia Reddy, Stanley B. Cohen
Publikováno v:
Current Opinion in Rheumatology. 33:300-306
Purpose of review To review recently published articles on use of Janus Kinase inhibitors (Jaki) in the clinic for rheumatoid arthritis (RA). Recent findings Several Jaki have been approved for RA patients failing csDMARDS. Over the last 2 years, EUL